Nielsen BioSciences is focused on developing innovative immunotherapies, particularly through its investigational product CANDIN, which is currently undergoing a Phase 3 clinical trial for the treatment of human papillomavirus (HPV) conditions, including common warts (Verruca vulgaris). CANDIN, which is already approved as a skin test antigen for assessing cellular hypersensitivity to Candida albicans, aims to activate the immune response to combat HPV. The company is exploring the potential of CANDIN to treat various viral dermatological conditions, with encouraging results from Phase 2 studies prompting further investigation into its efficacy against multiple wart types, including plantar and genital warts.

In addition to CANDIN, Nielsen BioSciences offers the SPHERUSOL skin test antigen, which is FDA-approved for assessing cell-mediated immunity to Coccidioides, the pathogen responsible for Valley Fever. This test is significant for monitoring immune responses in individuals with a history of coccidioidomycosis. The company’s research and development efforts are centered on leveraging biological products that enhance cell-mediated immune responses, addressing unmet medical needs in the treatment of viral infections and related conditions.

United States

Nielsen BioSciences, Inc. is a private, San Diego-based biotechnology company focused on offering medical professionals trusted and valued biological products with wide-ranging applications of cell-mediated immune responses. We are building on a solid foundation of over 40 years developing and delivering antigen-based products.

Our research and development leverages heterogeneous antigenic profiles to enlist cell-mediated immunity in the evaluation, treatment, or prevention of diseases. Antigenic diversity enables us to effectively address conditions missed by narrowly targeted strategies

Nielsen BioSciences

Company Details